Johnson & Johnson (JNJ)[Tv]

Key Developments

• FDA De Novo approval of OTTAVA robotic surgery platform marks a transformative entry into the $10 billion+ surgical robotics market, positioning JNJ as a direct challenger to Intuitive Surgical and validating its bold pivot into high-growth MedTech.
• FDA clearance of MONARCH QUEST 3 AI-powered bronchoscopy system establishes JNJ as a key player in AI-driven diagnostics, creating a scalable platform for recurring revenue and digital health dominance.
• $5.5 billion talc settlement framework secured in July 2026 represents a major milestone in resolving decades-long litigation, bringing closure to a persistent overhang and freeing capital for innovation and shareholder returns.
• FDA approval of Imaavy (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA) is a first-in-class breakthrough, validating JNJ’s rare disease immunology platform with $5 billion+ peak sales potential.
• Chinese approval of Icotyde, an oral IL-23 inhibitor for psoriasis, signals a pivotal expansion into the high-growth oral therapy segment, directly challenging injectable competitors like Skyrizi and Tremfya.